bc-264 and Substance-Withdrawal-Syndrome

bc-264 has been researched along with Substance-Withdrawal-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for bc-264 and Substance-Withdrawal-Syndrome

ArticleYear
Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats.
    Neuroscience letters, 1998, Mar-06, Volume: 244, Issue:1

    The conditioned place aversion paradigm was used to investigate the role of cholecystokinin in the aversive/dysphoric component of morphine abstinence. Several cholecystokinin ligands were chronically administered during the development of morphine dependence: the CCKA antagonist devazepide, the CCKB antagonists PD-134,308 and L-365,260, and the CCKB agonist BC 264. The CCK-B antagonists L-365,260 and PD-134,308 decreased and completely blocked (respectively) the place aversion induced by naloxone in morphine dependent animals whereas BC 264 and devazepide were inactive in this model. No effect was observed in non-dependent animals after chronic administration of these CCK-ligands. These results show a distinct role for CCK receptors in the regulation of the motivational component of morphine abstinence, probably related to their differential effects in the regulation of limbic dopaminergic neurons.

    Topics: Animals; Anti-Anxiety Agents; Avoidance Learning; Benzodiazepinones; Cholecystokinin; Conditioning, Classical; Devazepide; Indoles; Male; Meglumine; Morphine Dependence; Peptide Fragments; Phenylurea Compounds; Rats; Rats, Wistar; Substance Withdrawal Syndrome

1998
Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats.
    Pharmacology, biochemistry, and behavior, 1994, Volume: 48, Issue:2

    The aim of this study was to investigate the possible interaction between neuronal cholecystokinin (CCK) and opiate dependence. Rats were made dependent to morphine and the ability of cholecystokinin-octapeptide (CCK-8) and Tyr(SO3H)-gNle-mGly-Trp-(NMe)Nle-Asp-Phe-NH2 (BC 264), a selective agonist of CCK-B receptors, to induce signs of morphine withdrawal after ICV injection was tested. Behavioral responses were compared to those occurring during the naloxone-precipitated morphine withdrawal syndrome. In contrast to naloxone, CCK-8 (0.1, 1, and 10 micrograms, ICV) did not precipitate any sign of withdrawal. BC 264 (0.1, 1, and 10 micrograms, ICV) induced a strong hyperlocomotion and wet dog shakes in morphine-dependent rats, the latter effect also observed in nondependent animals. In rats receiving acute morphine, BC 264 induced an opposite effect (i.e., blockade of morphine-induced hyperactivity). Taken together, these results suggest that CCK plays only a minor role in the expression of morphine physical dependence.

    Topics: Amino Acid Sequence; Animals; Behavior, Animal; Cholecystokinin; Injections, Intraventricular; Male; Molecular Sequence Data; Morphine Dependence; Motor Activity; Naloxone; Peptide Fragments; Rats; Rats, Wistar; Receptors, Cholecystokinin; Substance Withdrawal Syndrome

1994